Search results
Results from the WOW.Com Content Network
[11] [12] Metronidazole is available orally (by mouth), as a cream or gel, and by slow intravenous infusion (injection into a vein). [11] [5] Common side effects include nausea, a metallic taste, loss of appetite, and headaches. [11] Occasionally seizures or allergies to the medication may occur. [11]
Common side effects include headache, nausea, sleepiness, and unsteadiness. [4] It is unclear if use during pregnancy causes risk to a fetus. [4] Fomepizole works by blocking the enzyme that converts methanol and ethylene glycol to their toxic breakdown products. [4] Fomepizole was approved for medical use in the United States in 1997. [4]
Side effects [ edit ] Though an effective antibiotic when all others fail, against extremely drug resistant infections, it has many side effects. including inhibition of monoamine oxidase , [ 1 ] and as with other nitrofurans generally, minimum inhibitory concentrations also produce systemic toxicity, resulting in tremors, convulsions ...
The approval of Appili's drug could help ease the metronidazole shortage in the U.S., especially for patients in hospitalized settings and those with severe i Canada's Appili gets US FDA approval ...
For people who are symptomatic, it is used after treatment with metronidazole or tinidazole. [2] It is taken by mouth. [1] Diloxanide generally has mild side effects. [3] Side effects may include flatulence, vomiting, and itchiness. [1] During pregnancy it is recommended that it be taken after the first trimester. [1]
[10] [11] It is used either by injection into a vein or by mouth. [10] When given for short periods, linezolid is a relatively safe antibiotic. [12] It can be used in people of all ages and in people with liver disease or poor kidney function. [10] Common side effects with short-term use include headache, diarrhea, rash, and nausea. [10]
Mefloquine, sold under the brand name Lariam among others, is a medication used to prevent or treat malaria. [4] When used for prevention it is typically started before potential exposure and continued for several weeks after potential exposure. [4]
In August 2023, the FDA approved canakinumab for the symptomatic treatment of adults with gout flares in whom nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate based on three studies.